Skip to main content

Table 2 Sample size requirements per trial arm, for three hypothetical trial scenarios, comparing differences between using DVR/SUVR, a cortical/early composite ROI, and restricting the inclusion to APOE-ε4 carriers or not

From: Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging

  Whole population APOE- ε4 carriers only
SUVR DVR SUVR DVR
Cortical ROI Early ROI Cortical ROI Early ROI Cortical ROI Early ROI Cortical ROI Early ROI
Secondary prevention to detect 20% reduction in accumulation (CL > 20.1) 176 167 143 140 116 125 83 97
Early secondary prevention to detect 20% reduction in accumulation (20.1 < CL ≤ 49.4) 44 51 39 38 52 56 47 43
Primary prevention to detect 20% reduction in accumulation (CL ≤ 20.1) 855 509 1508 734 724 455 1162 630